Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa, Herceptin, and Taxotere in HER2+ Metastatic Breast Cancer
NCT00086957Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jan 2004
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in breast cancer, sponsored by City of Hope. Primary endpoints: Number of Participants With at Least One Dose Limiting Toxicity at 4 weeks and Recommended Phase II Dose at 4 weeks. Started Jan 2004; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00086957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086957.